Alternatives to Evozyne

AI research lab developing frontier models for protein design and biological discovery.

Biotechnology company developing novel protein-based antimicrobial therapeutics.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

AI safety and research company building reliable, interpretable, and steerable AI systems.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Global supplier of life science research tools, including antibodies, reagents, and assays.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A vertically-integrated procurement platform for the life sciences industry.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

BreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

Developing novel immunotherapies and diagnostics for cancer.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Developing gene editing therapies to lower cholesterol.

AI-powered knowledge discovery for life sciences.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

Engineering scalable gene therapies for broader patient populations.

AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing ultrasound-mediated nonviral genetic medicines.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing highly targeted, small molecule medicines.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

AI-powered antibody discovery platform.

Advancing next-generation mRNA medicines.

Developing novel therapies to reverse aging and extend lifespan.

AI-powered antibody discovery platform.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A full-stack spatial biology company.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Nimbus Therapeutics is a clinical-stage biotech company using computational drug discovery to develop small molecule medicines.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Unlocking industrial-scale RNA-seq for primary drug screening and toxicology.